Navigation Links
Cleveland Clinic research finds no benefit over placebo in ASSURE trial

Monday, Sept. 3, 2013, Cleveland: Patients with coronary artery disease and low levels of "good cholesterol or high-density lipoprotein (HDL) who were treated with a drug designed to increase HDL levels and reduce coronary plaque build-up, experienced no better results than those treated with placebo, according to research conducted by the Cleveland Clinic Coordinating Center for Clinical Research (C5Research).

The drug, RVX-208, induces the production of apolipoprotein A1 (apoA1), a major protein in HDL. Prior research has shown that higher levels of HDL are associated with improved coronary health, so the ASSURE trial was designed to test whether increased production of apoA1 with the drug RVX-208 would raise HDL levels and slow the progression of coronary atherosclerosis, or plaque build-up in the coronary arteries.

The results of the ASSURE (ApoA1 Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation) trial were presented at the European Society of Cardiology Congress 2013. ASSURE was a prospective, randomized, multicenter, double-blind clinical trial.

A team of researchers led by Stephen J. Nicholls, M.D., Ph.D., senior consultant to Cleveland Clinic's C5Research and Professor of Cardiology and Deputy Director at the South Australian Health & Medical Research Institute (SAHMRI) in Adelaide, Australia, used intravascular ultrasonography (IVUS) to assess the degree of coronary disease in study subjects at baseline and after 26 weeks on oral RVX-208 or placebo. IVUS is a medical imaging technology in which a small ultrasound probe is inserted via a catheter into an artery, allowing physicians to examine the inside of arteries via sonogram. The researchers also took baseline and 26-week measurements of apoA1 and HDL.

The primary endpoint the change in percent atheroma volume (PAV), or the amount of artery volume taken up by disease was not met. The PAV decreased by 0.4 percent in the RVX-208 group and 0.3 percent in the placebo group. Secondary IVUS endpoints the change in total atheroma volume (TAV), or size of the disease, and the change in atheroma volume in the most severely diseased portion of the artery also did not differ substantially between the RVX-208 group and the placebo group. Further, the biochemical endpoints of increased aopA1 and HDL levels, and decreased LDL, or bad cholesterol levels, also failed compared to placebo.

"Our results show that RVX-208 treatment did not result in any measurable incremental benefit on plaque regression for patients with coronary artery disease and low HDL cholesterol," said Nicholls. "The findings could reflect either a lack of efficacy of RVX-208, or the general inability to improve on the benefits produced by statins and other cardiovascular therapies."

All of the patients in ASSURE were being treated with atorvastatin or rosuvastatin, drugs shown in clinical trials to lower LDL levels.

"Ever since statins were approved more than 25 years ago, there has been an intensive, concerted effort in the scientific community to find an HDL-raising drug that will work in tandem with statins and improve cardiovascular outcomes," said Steven Nissen, M.D., Chairman of the ASSURE trial and Chairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine at Cleveland Clinic. "Unfortunately, that search must go on."


Contact: Wyatt DuBois
Cleveland Clinic

Related medicine news :

1. Cleveland Clinic research finds blood pressure drug tends to slow coronary disease
2. Cleveland Clinic researcher finds genetic mutation in castration-resistant prostate cancer
3. CE Lectures on the Dental Treatment of Snoring and Sleep Apnea Include Rochester, Cleveland and Ft. Lauderdale, as Sleep Seminar Destinations
4. Cleveland Indians vs. Detroit Tigers Tickets: Cheap Concert Tickets Slashes Prices on All Indians vs. Tigers Tickets for August 5th - August 8th Series Progressive Field
5. National Transitions of Care Coalition to Host Regional Summit in Cleveland
6. Maroon 5 & Kelly Clarkson Ticket Prices Slashed for Concerts in Long Island, Holmdel, Cincinnati, Pittsburgh, Camden/Philly, Boston/Mansfield, Chicago, Cleveland & Detroi
7. Explorys Proud to Sponsor Cleveland GiveCamp
8. NEONI Participates in Healthcare Career Event at Cleveland Convention Center Grand Opening
9. Cleveland Clinic Laboratories to provide testing and diagnostic services to ACL Laboratories
10. Book of Mormon Tickets: Prices Slashed on Book of Mormon Tickets in New York, Chicago, Cleveland, Buffalo, Washington DC, Minneapolis, Houston and San Antonio
11. Cancer Survivor David Emerson Awarded Volkswagen Cup at Cleveland Marathon
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... transport experience for the millions of people who require these medical transport services ... industry through the use of technology. Now, SmartEMS has put forth an industry-changing ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating ... many ways they remain in the eye of the beholder, according to experts who ... of The American Journal of Managed Care. For the full issue, click here ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... Market Analysis 2016 - Forecast to 2022" report to ... report contains up to date financial data derived from varied ... major trends with potential impact on the market during the ... segmentation which comprises of sub markets, regional and country level ...
Breaking Medicine Technology: